Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

Coverage, in order

1. 15d ago
   
   MedCity News indie study

   Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva

   Artiva Biotherapeutics attributed one of the fatalities to a drug used to prepare patients for cell therapy and not to the cell therapy itself. But Artiva’s setbacks follow safety signals reported for autoimmune disease cell therapy programs from Novartis and Bristol Myers Squibb.

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.